<DOC>
	<DOC>NCT01740427</DOC>
	<brief_summary>The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.</brief_summary>
	<brief_title>A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy. Confirmed diagnosis of ER positive breast cancer No prior systemic anticancer therapy for advanced ER+ disease. Postmenopausal women Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or boneonly disease Eastern Cooperative Oncology Group [ECOG] 02 Adequate organ and marrow function Patient must agree to provide tumor tissue Confirmed diagnosis of HER2 positive disease Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term Known uncontrolled or symptomatic CNS metastases Prior (neo)adjuvant treatment with letrozole or anastrozole with DFI â‰¤ 12months from completion of treatment. Prior treatment with any CDK 4/6 inhibitor.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>postmenopausal women</keyword>
	<keyword>estrogen-receptor positive</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>locoregionally recurrent</keyword>
	<keyword>metastatic</keyword>
	<keyword>Palbociclib (PD-0332991)</keyword>
	<keyword>PALOMA-2</keyword>
</DOC>